Quantcast
Home > Quotes > RCUS

Arcus Biosciences, Inc. Common Stock (RCUS) Quote & Summary Data

RCUS 
$12.58
*  
0.33
2.69%
Get RCUS Alerts
*Delayed - data as of Dec. 13, 2018  -  Find a broker to begin trading RCUS now
Exchange:NYSE
Industry: Health Care
Community Rating:
View:    RCUS Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

1 Year Target
22
Today's High / Low
$ 12.75 / $ 12.07
Share Volume
206,118
90 Day Avg. Daily Volume
136,814
Previous Close
$ 12.25
52 Week High / Low
$ 22.10 / $ 9.50
Market Cap
559,264,770
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.93

Intraday Chart

Shares Traded

Share Volume:
206,118
90 Day Avg. Daily Volume:
136,814

Trading Range

The current last sale of $12.58 is 32.42% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 12.75 $ 22.10
 Low: $ 12.07 $ 9.50

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies by leveraging underexploited biological opportunities. Specifically, we target well-characterized biological pathways with significant scientific data supporting their importance in regulating the immune response against cancer and for which either there are no molecules in development or those that exist have suboptimal profiles. To exploit these pathways, we have built a robust and highly efficient discovery capability to create and optimize highly differentiated small-molecule immuno-oncology product candidates. Since our inception in 2015, we have built a broad portfolio of small-molecule and antibody product candidates that we plan to develop together as intra-portfolio combinations.  ... More ...  


Risk Grade

Where does RCUS fit in the risk graph?


Risk Grade Scale

Consensus Recommendation

Analyst Info